Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DPCM29
|
|||
| Drug Name |
CAEL-101
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Al amyloidosis [ICD-11: 5D00.0] | Phase 3 | [1] | |
| Company |
Alexion AstraZeneca Gene Therapy Cambridge, MA
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04504825) A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Na?ve Patients With Mayo Stage IIIb AL Amyloidosis. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.